Horus Pharma becomes additional commercialization partner for Formycon’s Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Formycon AG / Key word(s): Agreement
17.09.2025 / 06:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
17.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at http://www.eqs-news.com
This news is powered by Ad Hoc News 
